Cancerous disease modifying antibodies

Abstract

The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

What is claimed is: 
     
       1. An isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 180706-02. 
     
     
       2. A humanized version of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 180706-02. 
     
     
       3. A chimeric version of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 180706-02. 
     
     
       4. The isolated hybridoma cell line deposited with the IDAC as accession number 180706-02. 
     
     
       5. An antigen binding fragment of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 180706-02. 
     
     
       6. An antigen binding fragment of a humanized version of the antibody produced by the hybridoma deposited with the IDAC as accession number 180706-02. 
     
     
       7. An antigen binding fragment of a chimeric version of the antibody produced by the hybridoma deposited with the IDAC as accession number 180706-02. 
     
     
       8. The isolated antibody of any one of  claim 1 ,  2 , or  3  conjugated with a member selected from the group consisting of cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells. 
     
     
       9. A composition, comprising in combination:
 an antibody of any one of  claim 1 ,  2 , or  3 ; and 
 a pharmaceutically acceptable carrier. 
 
     
     
       10. A composition, comprising in combination:
 the isolated antibody of any one of  claim 1 ,  2 , or  3  conjugated with a member selected from the group consisting of cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells; and 
 a pharmaceutically acceptable carrier. 
 
     
     
       11. The antigen binding fragment of any one of  claim 5 ,  6 , or  7  conjugated with a member selected from the group consisting of cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells. 
     
     
       12. A composition, comprising in combination:
 an antigen binding fragment of any one of  claim 5 ,  6 , or  7 ; and 
 a pharmaceutically acceptable carrier. 
 
     
     
       13. A composition, comprising in combination:
 the antigen binding fragment of any one of  claim 5 ,  6 , or  7  conjugated with a member selected from the group consisting of cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells; and 
 a pharmaceutically acceptable carrier.